Immix Biopharma and 2 Other Penny Stocks to Watch Amidst US Market Rise

Immix Biopharma is a clinical-stage biopharmaceutical company developing CAR-T cell therapy for light chain amyloidosis and immune-mediated diseases. With a market cap of $65.74 million, the company is pre-revenue and faces financial challenges. Despite promising developments in its NXC-201 therapy, Immix's management and board are considered experienced but profitability is not anticipated in the near term. The stock has experienced high volatility, typical for penny stocks.

Immix Biopharma, a clinical-stage biopharmaceutical company, has been making significant strides in the development of CAR-T cell therapy for light chain amyloidosis (AL amyloidosis) and other immune-mediated diseases. The company's stock has experienced high volatility, reflecting the typical challenges faced by penny stocks. Despite these challenges, Immix's management and board are considered experienced, and the company has shown promising developments with its lead therapy, NXC-201.

NXC-201 is a sterically-optimized CAR-T construct designed to treat AL amyloidosis and other serious diseases. The proprietary N-GENIUS platform produced NXC-201, which includes a "digital filter" to reduce non-specific activation, enhancing tolerability. This construct is the only CAR-T in development specifically for AL amyloidosis, a market with a significant unmet need. The relapsed/refractory AL amyloidosis target market has a patient prevalence of 34,600 in the U.S., with no FDA-approved drugs currently available [1].

Immix has made notable progress in its clinical trials. The company reported interim results for its NEXICART-2 Phase 1/2 clinical trial with a registrational design at the American Society of Clinical Oncology (ASCO) oral presentation in 2024. The trial enrolled 10 patients, with the first patient dosed at Memorial Sloan Kettering Cancer Center. The company plans to submit a Biologics License Application (BLA) for NXC-201 in the fourth quarter of 2024 [2].

The N-GENIUS platform's sterically-optimized CAR-T construct includes a "digital filter" that reduces non-specific activation, leading to better tolerability. This proprietary construct is designed to enhance the binding and activation of plasma cells, ensuring high expression and reducing cytokine release. The company has also secured FDA Orphan Drug Designation (ODD) and Regenerative Medicine Advanced Therapy (RMAT) Designation for NXC-201 [3].

While Immix's management and board are experienced, the company faces financial challenges. The market cap of $65.74 million reflects the company's pre-revenue status, and profitability is not anticipated in the near term. However, the company's progress in developing NXC-201 and its experienced team may provide a pathway to future growth and profitability.

References:

[1] https://www.marketscreener.com/news/immix-biopharma-presentation-immx-corporate-presentation-september-2025-ce7d59dadb8af724
[2] E Lebel et al. Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) for the Treatment of Relapsed and Refractory AL Amyloidosis. Presentation. ASH 2024. M. Assayag, et al. Asherie N, et al. Development and manufacture of novel locally produced anti-BCMA CAR T cells for the treatment of relapsed/refractory multiple myeloma: results from a phase I clinical trial. Haematologica. 2023 Jul 1;108(7):1827-1839. doi: 10.3324/haematol.2022.281628. PMID: 36200421; PMCID: PMC10316256.
[3] Quock TP, et al. Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood Adv. 2018 May 22;2(10):1046-1053. doi: 10.1182/bloodadvances.2018016402. PMID: 29748430. Bazarbachi AH et al. Timing and outcomes of second-line therapy in the era of daratumumab-based frontline therapy in AL amyloidosis. Am J Hematol. 2024 Nov;99(11):2225-2228. doi: 10.1002/ajh.27450. Epub 2024 Aug 3. PMID: 39096115. Zanwar S, et al. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures. Leukemia 2024.